Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma

Blood. 2018 Nov 8;132(19):2097-2100. doi: 10.1182/blood-2018-05-851170. Epub 2018 Sep 20.

¹ Department of Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
² Department of Hematology and Oncology, University Hospital Zurich, Zurich, Switzerland.
³ Department of Medical Oncology, Inselspital, Universitätsspital Bern, Bern, Switzerland.
⁴ Division of Hematology, Kantonsspital Aarau AG, Aarau, Switzerland.
⁵ Division of Oncology and Hematology, HFR Fribourg, Fribourg, Switzerland.
⁶ University Hospital Geneva, Geneva, Switzerland.
⁷ Division of Hematology, Luzerner Kantonsspital, Lucerne, Switzerland.
⁸ Kantonsspital Graubünden, Chur, Switzerland.
⁹ Universitaetsspital Zurich, Zurich, Switzerland.
¹⁰ Coordinating Center, International Breast Cancer Study Group, Bern, Switzerland.
¹¹ Coordinating Center, Swiss Group for Clinical Cancer Research, Bern, Switzerland; and.
¹² Department of Medical Oncology, Luzerner Kantonsspital, Lucerne, Switzerland.

No abstract available

Publication types